Each year the Bursky Center for Human Immunology & Immunotherapy Programs hosts an annual symposium which profiles advances in the field of human immunology. 

Mark your calendars for March 19, 2020 for the Fourth Annual Bursky Symposium.

Jump to a section below to see highlights from past symposiums:

Third Annual Symposium Highlights

On Tuesday, March 7, 2019, the third annual symposium was held.  The symposium featured distinguished scientists including a Nobel Prize Laureate and profiled remarkable advances in the development of treatment options for cancer, infectious diseases, autoimmune disorders, and brain tumors.  The following list highlights featured talks:

  • “Immune Checkpoint Blockade in Cancer Therapy: Historical Perspective, New Insights, and Prospects for Cures”
    James P. Allison, PhD
    Professor and Chair, Department of Immunology
    University of Texas, MD Anderson Cancer Center
    Nobel Prize in Physiology or Medicine 2018
  • “ILC Recognition of Tumor Cells”
    Marco Colonna, MD
    Robert Rock Belliveau MD Professor, Pathology & Immunology
  • “Human Tuberculosis: A moving target”
    Shabaana Khader, PhD
    Professor and Interim Chair, Molecular Microbiology
  • “Genetic Variants in Complement Regulators Causing Human Disease”
    John P. Atkinson, MD
    Samuel B. Grant Professor, Medicine, Division of Rheumatology
    Professor, Molecular Microbiology
Robert Schrieber, PhD and James P. Allison, PhD

Second Annual Symposium Highlights

On Tuesday, February 27, 2018, the second annual symposium was held.  The symposium featured distinguished scientists and profiled remarkable advances in the development of treatment options for cancer, infectious diseases, autoimmune disorders, and brain tumors.  The following list highlights featured talks:

  • “Impressions of the New NCI Director”
    Norman E. “Ned” Sharpless, MD
    Director, National Cancer Institute
  • “Things I Learned at Washington University and Industry about Drug Discovery and Development”
    Philip Needleman, PhD
    Professor & Chair Emeritus, Department of Pharmacology
  • “Leveraging Neoantigen Discovery in Glioblastoma”
    Gavin Dunn, MD, PhD
    Assistant Professor of Neurological Surgery, Pathology & Immunology
    Bursky Scholar
  • “One in a Billion: Diagnosis and Treatment of Rare Pediatric Immune Diseases”
    Megan Cooper, MD, PhD
    Assistant Professor of Pediatrics, Pathology & Immunology
  • “From Autoimmunity to Zika: Understanding Links between Cell-Intrinsic Innate Immunity, Viruses and Autoimmunity”
    Jonathan Miner, MD, PhD
    Assistant Professor of Medicine, Molecular Microbiology, Pathology & Immunology

Inaugural Symposium Highlights

On Thursday, February 2, 2017, the inaugural symposium was held.  The symposium featured distinguished scientists and profiled remarkable advances in the development of treatment options for cancer, infectious diseases, autoimmune disorders, and brain tumors.  The following list highlights featured talks:

  • “Advances in Personalized Cancer Immunotherapy”
    Robert D. Schreiber, PhD
    Andrew M. and Jane M. Bursky Distinguished Professor
    Director, Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs
  • “New Insights into Human Diseases Caused by Immune System Dysfunction”
    Wayne M. Yokoyama, MD
    Sam J. Levin and Audrey Lowe Levin Professor of Arthritis Research
    Associate Director, Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs
  • “Discoveries in Basic Biology of Infectious Diseases and Their Rapid Transition to Drug and Vaccine”
    Michael S. Diamond, MD, PhD
    Herbert S. Gasser Professor
    Associate Director, Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs
  • “Innovation, Crisis and the Role of Biotechnology”
    Robert I. Tepper, MD
    Partner and Co-Founder, Third Rock Ventures, LLC
  • “Building Better Medicines: The Role of the Biopharmaceutical Industry”
    Roger M. Perlmutter, MD, PhD
    Executive Vice President, Merck & Co.
    President, Merck Research Laboratories